Clinical significance of PET/CT molecular cell diagnostics of inflammatory diseases of the urinary system

B.A. Berdichevsky, V.B. Berdichevsky, E.V. Sapozhenkova, I.V. Pavlova, A.R. Gonyaev, A.L. Boldyrev, V.A. Shidin, N.V. Averina, A.V. Simonov, M.A. Korabelnikov

1) FGBOU VO Tyumen State Medical University of the Ministry of Health of Russia, Tyumen, Russia; 2) Regional Clinical Hospital No. 2, Tyumen, Russia; 3) Medical Sanitary Department «Neftyanik», Tyumen, Russia; 4) Clinical Hospital «Mother and Child», Tyumen, Russia; 5) Radiological Center GAUZ TO MC «Medical City», Tyumen, Russia; 6) Pathological and anatomical bureau of GAUZ TO MC «Medical City», Tyumen, Russia

Introduction. The formation of a local pathological process is associated with a disturbance of functional molecular bonds both inside the cell and in the intercellular space surrounding it. It precedes the appearance of laboratory and clinical manifestations of the disease and is available for non-invasive analysis only by PET/CT scanning.
Aim. To determine the clinical significance of PET/CT scanning in molecular cell diagnosis of inflammatory diseases of the urinary
system.
Materials and methods. A comparative study of the results of whole-body PET/CT with 11C-choline and 18F-FDG glucose was carried out with a comparison with the results of kidney and bladder morphobiopsy in 96 urological patients, including 56 women and 40 men with a median age of 51.5 (37; 61). They were randomized into three equal groups: without clinical and laboratory manifestation of urological diseases, with isolated urinary syndrome and clinical and laboratory manifestation of pathology.
Results. A synchronous decrease in the metabolism of 11C-choline and 18F-FDG glucose in the kidney parenchyma and a significant increase in the bladder wall were revealed, which correlated with the severity of clinical and laboratory manifestations.
Conclusion. PET/CT technology for studying lipid and carbohydrate metabolism in the organs of the urinary system can be recommended as an additional method for diagnosing urological disorders at the early molecular-cellular stages and during navigation during targeted biopsy.

Keywords

About the Authors

Corresponding author: B.A. Berdichevsky – Ph.D., MD, professor at the Department of Oncology with a course of Urology of FGBOU VO Tyumen State Medical University of the Ministry of Health of Russia, Tyumen, Russia; e-mail: doctor_bba@mail.ru

Similar Articles